We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Feb 2023 - 18 Feb 2023

World’s Smallest Heart Pump Maintains Blood Pressure and Flow During Stent Placement

By HospiMedica International staff writers
Posted on 18 Aug 2022
Print article
Image: The world’s first patient has been implanted with Impella BTR minimally invasive heart pump (Photo courtesy of Abiomed)
Image: The world’s first patient has been implanted with Impella BTR minimally invasive heart pump (Photo courtesy of Abiomed)

Patients with coronary artery disease may undergo a procedure called Percutaneous Coronary Intervention (PCI), commonly known as angioplasty or stenting. This minimally invasive heart procedure uses a small catheter to take pictures and deliver tools that are used to open or unblock arteries narrowed by plaque. The most common type of PCI is angioplasty, during which a tiny balloon is inflated to compress the plaque against the sides of the artery to help blood flow better. During a PCI, interruptions of coronary blood flow can cause problems, especially for patients with severe heart disease. As a result, patients with health risks such as diabetes, kidney disease, or anatomic issues with the heart may not be qualified for a conventional PCI. Now, a new stenting procedure may be an option for some patients with these additional health risks.

The new stenting procedure known as Protected PCI is designed to treat complex coronary artery disease and includes the use of the Impella heart pump from Abiomed, Inc. (Danvers, MA, USA). The use of an Impella heart pump during a PCI allows blood pressure and blood flow to be maintained during the procedure, which may allow surgeons to perform a more complete and optimized procedure. Impella is temporarily inserted through a small incision and advanced through the arteries and into the heart. Once in place, the Impella heart pump is turned on, pulling blood from the left ventricle and releasing it into the aorta. This active ‘unloading’ of the left ventricle increases blood flow to the brain and other vital organs and protects the kidneys from acute injury. When the heart is strong enough to pump on its own and the Impella heart pump is no longer needed, the cardiologist removes it before discharging the patient from the hospital.

Impella, the world’s smallest heart pump, is the only FDA-approved, non-surgical heart pump proven safe and effective to assist the pumping function of the heart during stent placement and ensure blood flow is maintained to critical organs. During a Protected PCI, or protected stenting procedure, the Impella heart pump is placed temporarily in the heart to assist the pumping function while the physician performs the necessary treatment (angioplasty, stent placement, etc.). Impella features SmartAssist technology that gives medical providers insights to help them improve patient outcomes through intelligent metrics. Impella, the world’s smallest heart pumps, are intended for temporary (less than or equal to six hours) use to maintain stable heart function.

Abiomed is now developing Impella Bridge-to-Recovery (BTR), a forward flow heart pump that is implanted via the axillary artery and sits in the left ventricle, can pump greater than six liters of blood per minute. It is smaller and less invasive than current LVADs and allows patients with chronic heart failure to have a longer-term minimally invasive heart pump option. Impella BTR’s design is intended to allow for heart recovery or heart remodeling with adjunctive therapies for patients with class III / IV heart failure. The vision of the Impella BTR development program is to provide a patient with home discharge and more than one year of full hemodynamic support. The first patient in the world has been successfully implanted with Impella BTR as part of the heart pump’s U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS).

“The first implant of Impella BTR is an important step toward our goal of improving patient care by providing a longer-term minimally invasive forward flow smart heart pump option with home discharge for patients with chronic heart failure,” said Michael Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “Overall, Abiomed is creating the innovation for the field of heart recovery and solving a healthcare crisis for this patient population with advanced research and technology.”

Related Links:
Abiomed, Inc. 

Gold Supplier
Premium Ultrasound Scanner
ARIETTA 850
New
Ultrasound System
HERA W10 Elite
New
Mechanical Ventilator
NKV-550 Series
New
Smart nCPAP Device
SVAAS nCPAP

Print article

Channels

AI

view channel
Image: A novel research study moves the needle on predicting coronary artery disease (Photo courtesy of Pexels)

AI-Enabled ECG Analysis Predicts Heart Attack Risk Nearly as well as CT Scans

Increased coronary artery calcium is a marker of coronary artery disease that can lead to a heart attack. Traditionally, CT scans are used to diagnose buildup of coronary artery calcium, although CT scanners... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Point of Care

view channel
Image: Steripath improves the diagnostic accuracy and timeliness of sepsis test results (Photo courtesy of Magnolia)

All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. However, positive blood culture results can be frequently wrong, and about... Read more

Business

view channel
Image: The global endoscopy equipment market is projected to surpass USD 40 billion by 2027 (Photo courtesy of Pexels)

Global Endoscopy Equipment Market Driven by Growing Hospital Investment in Advanced Instruments

The global endoscopy equipment market is projected to register a CAGR of 7% from USD 28.9 billion in 2022 to USD 40.6 billion by 2027, driven by increasing demand for endoscopy to diagnose and treat target... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.